These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29909790)

  • 41. A review of second-generation antipsychotic discontinuation in first-episode psychosis.
    Miller BJ
    J Psychiatr Pract; 2008 Sep; 14(5):289-300. PubMed ID: 18832960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perceptions of relapse risks following first-episode psychosis and attitudes towards maintenance medication: a comparison between nursing and social work professionals.
    Chan KK; Chin QP; Tang JY; Longenecker J; Hui CL; Chiu CP; Lam MM; Wong GH; Chen EY
    Early Interv Psychiatry; 2011 Nov; 5(4):324-34. PubMed ID: 21521490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aripiprazole for schizophrenia.
    El-Sayeh HG; Morganti C
    Cochrane Database Syst Rev; 2004; (2):CD004578. PubMed ID: 15106256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review.
    Bowtell M; Ratheesh A; McGorry P; Killackey E; O'Donoghue B
    Schizophr Res; 2018 Jul; 197():9-18. PubMed ID: 29146020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The evaluation and treatment of first-episode psychosis.
    Sheitman BB; Lee H; Strous R; Lieberman JA
    Schizophr Bull; 1997; 23(4):653-61. PubMed ID: 9366001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review.
    Salgueiro M; Segarra R
    Int Clin Psychopharmacol; 2019 Mar; 34(2):51-56. PubMed ID: 30540617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability.
    Noguera A; Ballesta P; Baeza I; Arango C; de la Serna E; González-Pinto A; Parellada M; Graell M; Moreno C; Otero S; Castro-Fornieles J
    J Clin Psychopharmacol; 2013 Aug; 33(4):463-71. PubMed ID: 23771198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does Slow and Steady Win the Race? Rates of Antipsychotic Discontinuation, Antipsychotic Dose, and Risk of Psychotic Relapse.
    McCutcheon RA; Taylor D; Rubio J; Nour J; Pillinger T; Murray RM; Jauhar S
    Schizophr Bull; 2024 Apr; 50(3):513-520. PubMed ID: 37797288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quetiapine versus typical antipsychotic medications for schizophrenia.
    Suttajit S; Srisurapanont M; Xia J; Suttajit S; Maneeton B; Maneeton N
    Cochrane Database Syst Rev; 2013 May; (5):CD007815. PubMed ID: 23728667
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Depot bromperidol decanoate for schizophrenia.
    Wong D; Adams CE; David A; Quraishi SN
    Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aripiprazole versus placebo for schizophrenia.
    Belgamwar RB; El-Sayeh HG
    Cochrane Database Syst Rev; 2011 Aug; (8):CD006622. PubMed ID: 21833956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protocol of guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis based on pragmatic design.
    Liu CC; Hsieh MH; Chien YL; Liu CM; Lin YT; Hwang TJ; Hwu HG
    Early Interv Psychiatry; 2022 Feb; 16(2):178-185. PubMed ID: 33751764
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Visual working memory deterioration preceding relapse in psychosis.
    Hui CL; Li YK; Li AW; Lee EH; Chang WC; Chan SK; Lam SY; Thornton AE; Sham P; Honer WG; Chen EY
    Psychol Med; 2016 Aug; 46(11):2435-44. PubMed ID: 27305830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Zuclopenthixol dihydrochloride for schizophrenia.
    Kumar A; Strech D
    Cochrane Database Syst Rev; 2005 Oct; (4):CD005474. PubMed ID: 16235403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early intervention for psychosis.
    Marshall M; Rathbone J
    Cochrane Database Syst Rev; 2006 Oct; (4):CD004718. PubMed ID: 17054213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chlorpromazine versus placebo for schizophrenia.
    Thornley B; Rathbone J; Adams CE; Awad G
    Cochrane Database Syst Rev; 2003; (2):CD000284. PubMed ID: 12804394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [
    Kim S; Shin SH; Santangelo B; Veronese M; Kang SK; Lee JS; Cheon GJ; Lee W; Kwon JS; Howes OD; Kim E
    Mol Psychiatry; 2021 Jul; 26(7):3476-3488. PubMed ID: 32929214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.
    Kishimoto T; Agarwal V; Kishi T; Leucht S; Kane JM; Correll CU
    Mol Psychiatry; 2013 Jan; 18(1):53-66. PubMed ID: 22124274
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Haloperidol versus placebo for schizophrenia.
    Joy CB; Adams CE; Lawrie SM
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003082. PubMed ID: 17054159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
    Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
    J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.